Mediplantex National Pharmaceutical JSC (HNX:MED)
Vietnam · Delayed Price · Currency is VND 18,400
0.00 (0.00%)
At close: May 13, 2026
HNX:MED Ratios and Metrics
Market cap in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 12, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 228,344 | 291,635 | 322,660 | 335,070 | 260,610 | 187,775 | |
Market Cap Growth | -32.60% | -9.62% | -3.70% | 28.57% | 38.79% | -23.33% |
Enterprise Value | 231,157 | 312,499 | 332,302 | 335,404 | 170,199 | 147,414 |
Last Close Price | 18400.00 | 23500.00 | 24660.94 | 24749.42 | 18879.37 | 26565.12 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 12, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 9.51 | 18.42 | 21.16 | 28.53 | 40.94 | 50.11 |
PS Ratio | 0.78 | 0.80 | 0.73 | 0.83 | 0.65 | 0.55 |
PB Ratio | 0.67 | 0.88 | 0.98 | 1.02 | 0.81 | 1.13 |
P/TBV Ratio | 0.67 | 0.88 | 0.98 | 1.02 | 0.81 | 1.13 |
P/FCF Ratio | 17.37 | - | 8.57 | - | - | 24.24 |
P/OCF Ratio | 12.61 | - | 6.77 | - | 9.94 | 3.02 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 12, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.79 | 0.85 | 0.75 | 0.83 | 0.42 | 0.43 |
EV/EBITDA Ratio | 15.60 | 10.56 | 11.04 | 14.83 | 9.12 | 8.00 |
EV/EBIT Ratio | 28.99 | 13.94 | 14.97 | 23.65 | 19.71 | 16.58 |
EV/FCF Ratio | 17.58 | - | 8.82 | - | - | 19.03 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 12, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.14 | 0.10 | 0.08 | 0.20 | 0.28 | 0.41 |
Debt / EBITDA Ratio | 3.26 | 1.15 | 0.92 | 2.85 | 4.87 | 3.72 |
Debt / FCF Ratio | 3.68 | - | 0.74 | - | - | 8.86 |
Net Debt / Equity Ratio | 0.05 | 0.01 | -0.08 | 0.00 | -0.26 | -0.16 |
Net Debt / EBITDA Ratio | 1.15 | 0.10 | -0.89 | 0.04 | -4.44 | -1.41 |
Net Debt / FCF Ratio | 1.30 | -0.19 | -0.71 | -0.01 | 0.91 | -3.34 |
Asset Turnover | 0.62 | 0.76 | 0.84 | 0.64 | 0.67 | 0.68 |
Inventory Turnover | 2.45 | 3.11 | 3.68 | 3.12 | 3.38 | 3.05 |
Quick Ratio | 0.59 | 0.56 | 0.72 | 0.69 | 0.83 | 0.70 |
Current Ratio | 1.59 | 1.63 | 1.46 | 1.32 | 1.22 | 1.04 |
Return on Equity (ROE) | 7.27% | 4.78% | 4.63% | 3.62% | 2.61% | 2.16% |
Return on Assets (ROA) | 1.05% | 2.92% | 2.62% | 1.41% | 0.91% | 1.09% |
Return on Invested Capital (ROIC) | 1.90% | 5.39% | 5.51% | 3.93% | 3.35% | 4.09% |
Return on Capital Employed (ROCE) | 2.30% | 6.80% | 6.70% | 4.30% | 2.70% | 5.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 12, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 10.52% | 5.43% | 4.72% | 3.50% | 2.44% | 2.00% |
FCF Yield | 5.76% | -5.19% | 11.68% | -25.22% | -34.93% | 4.13% |
Dividend Yield | 6.52% | - | - | 3.64% | 2.65% | 0.94% |
Payout Ratio | 62.46% | 94.72% | 72.28% | 54.72% | 138.49% | 354.43% |
Buyback Yield / Dilution | -0.03% | - | - | -32.18% | -49.59% | 0.05% |
Total Shareholder Return | 6.50% | - | - | -28.54% | -46.94% | 0.99% |